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Animal models have extensively contributed to our understanding of human immunobi-
ology and to uncover the underlying pathological mechanisms occurring in the develop-
ment of diseases. However, mouse models do not reproduce the genetic and molecular 
complexity inherent in human disease conditions. Human immune system (HIS) mouse 
models that are susceptible to human pathogens and can recapitulate human hemato-
poiesis and tumor immunobiology provide one means to bridge the interspecies gap. 
Natural killer cells are the founding member of the innate lymphoid cell family. They exert 
a rapid and strong immune response against tumor and pathogen-infected cells. Their 
antitumor features have long been exploited for therapeutic purposes in the context 
of cancer. In this review, we detail the development of highly immunodeficient mouse 
strains and the models currently used in cancer research. We summarize the latest 
improvements in adoptive natural killer (NK) cell therapies and the development of novel 
NK cell sources. Finally, we discuss the advantages of HIS mice to study the interactions 
between human NK cells and human cancers and to develop new therapeutic strategies.
Keywords: humanized mouse models, innate lymphoid cell, natural killer cells, cancer immunotherapy, natural 
killer cell immunotherapy
iNTRODUCTiON
Since the generation of the first inbred mouse strains in the early 20th century, mice have served as 
model organisms to study mammalian biology. This approach has given birth to some of the most 
important scientific breakthroughs and discoveries that, in many cases, led to the development of 
successful treatments for previously untreatable diseases (e.g., acute promyelocytic leukemia) (1). 
However, Mus musculus and Homo sapiens have been evolving divergently for 85 million years, 
adapting to very different environments and undergoing selection for many traits, from the circa-
dian rhythm to our body size (2). Thanks to the genome decoding, we can now appreciate that the 
one fifth of the genetic divergence between mice and humans is enriched in regions implicated in 
the immune system, metabolic processes, and stress responses (3). It is, therefore, not surprising 
that only less than 8% of the cancer studies in animal models reach clinical trials and that more than 
80% of these eventually fail when tested in humans (4). The increasing knowledge of the molecular 
differences between mice and humans should allow us to evaluate the degree in which animal 
models may be suitable for translational research and when this is not the case, to then search for 
better systems.
With this aim, mice have been “humanized” by introducing human genes or genomic regions and 
by transferring human tissues or cells to study various aspects of human biology. The engraftment 
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of human blood cells or blood-forming cells and organs into 
immunodeficient mice has opened a new era for translational 
immunology and the improvement of immunotherapies against 
human cancer and infectious diseases caused by pathogens with 
exclusive human tropism, such as HIV, HBV, and HCV.
DeveLOPiNG HUMAN iMMUNe SYSTeM 
(HiS) MiCe
Since the discovery of the nude athymic mutations in the 1960s, 
our knowledge of the host immune system and its ability to 
reject xenografts have led to the development of several mouse 
strains that permit long-term “take” and function of the human 
tissue grafts (5). Experiments performed in the 1980s with severe 
combined immunodeficient (SCID) mice (that lacked functional 
mouse adaptive lymphocytes due to mutations in the DNA-
dependent protein kinase Prkdc) showed that these mice could 
be reconstituted with human peripheral blood mononuclear cells 
(PBMCs) or hematopoietic stem cells (HSCs) (6, 7). However, 
some residual adaptive (leakiness) and an essentially intact innate 
immunity in SCID mice limited the complete reconstitution of all 
human immune subsets. Moreover, SCID mice failed to engraft 
human tumor xenografts, thereby limiting the development of 
preclinical cancer models. An alternative system with analogous 
immunodeficiency was obtained by mutating the recombinant 
activating genes (Rag1, Rag2) loci that avoided genetic “leakiness” 
and, in contrast to SCID mice, did not result in host radiosensitiv-
ity (8, 9). Additional genetic modifications followed to further the 
immunodeficiency of host mice in order to promote tolerance to 
human cells. Two breakthroughs have remarkably boosted the 
advancement of the field. First, Greiner and colleagues found that 
the NOD strain supported an enhanced tolerance compared to 
other strains and, several years later, Takenaka’s team revealed that 
the molecular basis for this lies in the signal regulatory protein 
alpha (Sirpa) allele polymorphism (10–13). Contrarily to other 
strains, SIRPα from NOD mice binds to human CD47 ligand 
triggering a negative signal in mouse macrophages that prevents 
their phagocytosis (13, 14). This finding prompted the generation 
of transgenic mice expressing the human or NOD strain Sirpa 
allele thus conferring enhanced human cell engraftment (15–17). 
The second turning point for achieving a successful xenotrans-
plantation was the common cytokine receptor gamma chain (γc, 
encoded at Il2rg), which leads to complete impairment of natural 
killer (NK) cell development and dendritic cell (DC) dysfunction 
(18, 19). Mice carrying Il2rg mutations were developed in various 
genetic backgrounds [NSG or NOG (both NOD PrkdcSCIDIl2rg−/−) 
and BRG (Balb/c Rag2−/−Il2rg−/−)] allowing robust, long-lasting de 
novo multilineage development of the HIS, including human thy-
mopoiesis, and are the basis for most of the currently used models 
(20–23). From that point forward, a number of model variants 
have been developed to address specific questions or improve 
particular aspects of immunity, either by genetic manipulation, 
engraftment of additional human tissues, or exogenous adminis-
tration of human factors. This is the case of the recently described 
Balb/c Rag2−/−Il2rg−/−Flt3−/− (BRGF) model with specific boost of 
conventional and plasmacytoid DCs after exogenous Flt3 ligand 
treatment. This model offers a great platform for screening of 
immune adjuvants and DC targeting therapies (24).
HUMAN CANCeR MODeLS iN 
“HUMANiZeD” MiCe
Immunodeficient mice allow great flexibility for the study of 
human tumor immunobiology. Human tumors can be generated 
in NSG, NOG, BRGS, and other strains using established tumor 
cell lines, after transplantation of human primary tumors or fol-
lowing de novo induction of hematological neoplasms (Figure 1). 
These different models provide systems that better reflect the 
complexity of the disease. In order to allow human tumor to 
engraft and grow in mice, the host immune system is generally 
compromised leading to tumor kinetics that may not reflect 
the true patient situation. As discussed earlier, human immune 
components can be generated in vivo from human HSCs or other 
progenitors and “supported or potentiated” later on or infused 
once the tumor is established. These approaches provide “mixed” 
systems in which human immune cells and human tumors can 
co-exist allowing the dissection of immune deviation as well as 
studying immunotherapy.
A wide range of established tumor cell lines from different 
origins (brain, colon, breast, melanoma, ovarian, prostate, etc.) 
have been engrafted in immunocompromised mice and have 
greatly contributed to drug development and the preclinical 
assessment of potential therapies. However, the gradual accumu-
lation of genetic and phenotypic aberrations in these cells due 
to their long-term culture impacts the surface markers and the 
tumorigenicity of the malignancy (25). These limitations have 
set aside these models to preliminary studies addressing specific 
questions like the ability of a potential therapy to target a certain 
molecule that has been overexpressed in the cell line. In recent 
years, the field has been, therefore, switching toward the engraft-
ment of patient-derived primary tumors (PDX, patient-derived 
xenografts) that retain the phenotypic and genetic complexity 
observed in clinical samples thus better predicting drug efficacy 
and clinical translatability (26, 27). These include tumor stromal 
cells and tumor-associated lymphocytes that contribute greatly 
to tumor growth and metastasis and, therefore, to the therapeutic 
response. These PDX-HIS mouse models can engraft the tumor as 
efficiently as the non-humanized mice, they respond to standard 
chemotherapeutic drugs similarly to patients and they have 
proven to be responsive to newly derived immune modulators.
One of the better-characterized PDX models is the AML that 
has contributed to the identification of leukemia stem cells (LSC) 
by transplanting different stem-like cell fractions and analyzing 
the leukemia-initiating activity of each in SCID mice (28–31). 
The discovery of the concept of cancer stem cell (CSC) has been a 
breakthrough in cancer biology due to the clinical benefits for the 
long-term disease-free survival. CSC presence has been identified 
in numerous other malignancies through transfer into immuno-
compromised mice and, interestingly, markers associated to CSCs 
have been correlated to the tumorigenic potential (32, 33). Recent 
improvements in HIS mouse models by the transgenic expres-
sion of certain factors, like the NSG-SGM3 expressing human 
FiGURe 1 | Human immune system (HiS) mouse models used in cancer research. PBMC, peripheral blood mononuclear cells; NSG, NOD PrkdcSCIDIl2rg−/−; 
BRG, Balb/c Rag2−/−Il2rg−/−; BRGS, Balb/c Rag2−/−Il2rg−/− SirpaNOD; HSC, hematopoietic stem cell; FT, fetal thymus; BM, bone marrow; CAR, chimeric antigen 
receptor; UCB, umbilical cord blood; ATLL, T-cell leukemia/lymphoma; AML, acute myeloid leukemia; EBV, Epstein–Barr virus (37–56).
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SCF, GM-SCF, and IL-3, have further ameliorate the engraftment 
and growth of human leukemia allowing the study of the tumor 
initiating cells (34). The demonstration that HIS mouse models 
reproduce the heterogeneity and behavior of human tumors cre-
ates great expectation on the better phenotyping of these tumor-
initiating cells and the identification of drugs targeting this key 
population (35).
One of the advantages of modeling cancer in humanized mice 
is that we can study the systemic environment and the contribu-
tion of nearly all the immune cells to the pathogenesis. In this 
regard, a NSG model of treatment-refractory B-cell leukemia 
revealed that infiltration of leukemia cells into the bone marrow 
rewires the tumor microenvironment to inhibit engulfment of 
antibody-targeted tumor cells. This resistance could be overcome 
by combination regimens involving therapeutic antibodies 
and chemotherapy that lead to macrophage infiltration and 
phagocytic activity in the bone marrow improving the efficacy of 
targeted therapeutics (36).
TARGeTiNG NK CeLLS FOR CANCeR 
iMMUNOTHeRAPY
To date, most immunomodulatory strategies have focused on 
agents or cell therapies targeting T  cell immunity. In contrast, 
innate immune cells, such as NK cells, have been less exploited. 
Nevertheless, the fundamental role for these cells has been for 
long justified by the higher cancer incidence in individuals with 
defective NK function (57). Furthermore, a number of mouse 
models lacking or deficient for NK cell function have corrobo-
rated their importance in tumor immunosurveillance (58).
Natural killer cells exert an immediate cytotoxicity when 
encountering a malignant cell and they do so without a specific 
antigen priming but instead, by the integrated signal of an array 
of activating and inhibitory receptors. Among the first group, 
the C-type lectin-like receptors CD94/NKG2C and NKG2D and 
the natural cytotoxicity receptors NKp30, NKp44, and NKp46 as 
well as the Ig-like receptor DNAM-1 (CD266) mediate NK cell 
activation when they recognize tumor cells. On the other hand, 
polymorphic inhibitory killer cell immunoglobulin-like recep-
tors (KIRs) with their cognate human–leukocyte–antigen (HLA) 
ligands as well as CD94/NKG2A with the non-classical class I 
molecule HLA-E as ligand provide inhibitory signaling. In addi-
tion to the contact mediated regulation of the activity, NK cells 
also respond to cytokines like IL-2, IL-12, IL-15, IL-18, and IL-21, 
as well as toll-like receptor ligands that shape their differentiation, 
proliferation, and activation status (59). Cytotoxicity activity is 
triggered through activation of the low-affinity activating recep-
tor FcγRIIIa (CD16) that binds the Fc portion of immunoglobulin 
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G1, which has been exploited in monoclonal antibody immuno-
therapies. NK  cells kill virus-infected and tumor cells using a 
cargo of perforin and granzymes contained in cytotoxic granules 
and less efficiently by a mechanism dependent on FAS ligand, 
TNF, or TNF-related apoptosis-inducing ligand (60).
Given that NK cells in HSC-derived humanized mice express 
all the afore-mentioned receptors and respond similarly to the 
same cytokines (61, 62), these in vivo models represent a pow-
erful platform to explore the pivotal role of NK cells in cancer 
immunosurveillance (63–65) (Lopez-Lastra et  al., in revision). 
Additionally, environmental components such as inhibiting fac-
tors (TGF-β, IL-10, prostaglandin E2…) and immunosuppressive 
cells (Tregs, MDSCs) that influence the NK cell antitumor activity 
have also been described in HIS mice, enabling the evaluation of 
therapeutic strategies targeting the suppression of NK cells (66).
Although chemotherapy is still the core of the current clinical 
anticancer treatments, immunomodulators have now regained 
expectations after the revolutionary discovery of the CTLA-4 
and PD-1 checkpoint inhibitors targeting T-cell activation (67). 
Humanized mice have proven to recapitulate the therapeutic 
effect of those antibodies as well as the side effects and have 
began to provide insights about the mechanism behind and 
possible strategies to improve them (68–70). The expression of 
these receptors on human NK cells suggests that they could also 
be targeted by checkpoint molecules and, therefore, contributes 
to the outcome of the therapy (71, 72). Indeed, mouse studies 
on a glioma model treated with activated NK cells preincubated 
with an anti-PD-1 blocking antibody showed an enhancement of 
the survival suggesting a role that must be explored in a human 
system (73).
ADOPTive TRANSFeR OF NK CeLLS FOR 
CANCeR THeRAPY
The potential of NK cells as innate effectors in cancer has been 
studied by the adoptive transfer of ex vivo expanded and/or 
activated NK cells in immunodeficient mice. Mice treated with 
adoptively transferred human NK cells show NK-mediated rejec-
tion of the engrafted human tumor and further administration 
of cytokines, such as IL-2 and IL-15 greatly improve the NK cell 
pool and their cytotoxic activity against transformed cell. These 
observations initially made in mice laid the foundation for 
the autologous NK  cell infusion therapies started in the 1980s 
for metastatic cancers (74). Preclinical assessment of cytokine 
regimens in other cancer models, such as the low-dose IL-2 in 
the spontaneous EBV-associated B-cell lymphoma in PBL-SCID 
mice, demonstrated reduction of the tumor load and survival 
prolongation (75), and preceded a number of clinical trials for 
both hematological and solid tumors (76–79).
The discovery that inhibitory KIRs binding to MHC-I mediate 
inhibition of NK cells opened a new path on NK cell immuno-
therapies. NOD/SCID cancer models served as a platform to 
confirm the higher efficacy of alloreactive NK cells for the treat-
ment of leukemia. Contrarily to T cells, NK cell do not provoke 
graft-versus-host disease (GVHD) in hematopoietic stem cell 
transplantation (HSCT) contexts but, instead, protect the patient 
against it and eliminate leukemia relapse and graft rejection (80). 
Later on, safety and efficacy of alloreactive NK cell infusion was 
confirmed in the clinic by Miller and colleagues in non-HSCT 
settings with patients suffering from metastatic melanoma, renal 
cell carcinoma, Hodgkin’s lymphoma, and refractory AML (81). 
For many years, allogeneic NK  cell infusions have been tested 
in the clinic with positive results and rare cases of mild toxicity 
(82). Strikingly, a recent pediatric clinical study has reported 
some patients suffering from acute GVHD after infusion of ex 
vivo expanded donor NK  cells in HLA-matched HSCT (83), 
rising the necessity to perform more robust preclinical testing 
in humanized models. One strategy to do so was illustrated in 
a recent study performed in NSG mice, in which an alloreactive 
NK cell subpopulation expressing KIR2DS2 but lacking inhibi-
tory KIR-HLA mismatch had dominant functional activation 
advantage to kill patient-derived glioblastoma cells (84). The 
regulation of the activity on infused NK cells has been classically 
based on HLA-KIR matching; however, other inhibitory recep-
tors are implicated on the inhibition of NK cell cytotoxicity. A 
recent study in NSG mice engrafted with human HSC has shown 
that anti-NKG2A antibodies can stimulate human NK cell kill-
ing in AML and ALL models bypassing the need to search for 
NK cell alloreactive donors (85). In vitro experiments have also 
pointed to an increased NK cell-mediated lysis of lymphoma and 
myeloma cells with allogeneic NK cell infusion in combination 
with monoclonal antibodies blocking inhibitory KIRs but this 
effect need to be confirmed in vivo (86, 87).
Another strategy to increase NK cell activity without aggravat-
ing the side-effects is the expression of chimeric antigen receptors 
(CARs) directed against tumor antigens. Preclinical evaluation of 
CD20 targeting primary NK cell infusion in humanized mice has 
led to a clinical trial on B-lineage acute lymphoblastic leukemia 
currently undergoing (88). Other preclinical trials using CAR-
engineered primary human NK cells are now being performed 
in lymphoma, leukemia, carcinomas, and neuroblastoma mouse 
models.
Natural killer cells are often infused in combination with 
immunomodulators that boost their antitumor effects or regulate 
their activity. CD16 receptor is targeted by many of those modu-
lators since it mediates antibody-dependent cellular cytotoxicity 
(ADCC) when it recognizes an antibody on a tumor cell, leading 
to target cell lysis. This mechanism has been exploited by using 
monoclonal antibodies targeted tumor antigens thus stimulating 
the endogenous or adoptive NK  cells. Evidences of NK  cell-
mediated ADCC and mild to moderate toxicity were observed 
in preclinical models and then confirmed for some cases in the 
clinical setting. Malignancies such as non-Hodgkin lymphoma 
with rituximab (anti-CD20), metastatic breast cancer with tras-
tuzumab (anti-HER2) or metastatic colorectal, and squamous cell 
carcinoma of the head and neck have been treated with monoclo-
nal antibodies together with NK cell infusions or in combination 
regimes extending the disease-free survival and overall survival 
of thousands of patients (89–91).
As mentioned before, CSCs are emerging as necessary targets 
to achieve cancer cures since current treatments eliminate the bulk 
of the tumor cells but rare resistant CSCs persist and lead to later 
tumor relapse (92). The upregulation of stress-induced antigens 
together with the ability of NK cells to target non-proliferating 
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cells suggest that NK  cells could effectively eliminate CSCs. 
Indeed, recent studies in pancreatic carcinoma-bearing NSG 
mice demonstrated the capacity of activated transferred NK cells 
to reduce intratumoral CSCs and tumor burden (93–95).
NOveL NK CeLL SOURCeS FOR 
ADOPTive THeRAPY OF CANCeR
Two of the parameters to consider when evaluating the safety of 
NK cell products in clinical applications are the cell source and 
the culture conditions before the infusion. GM-CSF mobilized 
PBMCs, bone marrow, or umbilical cord blood (UCB) are the 
main sources of NK cells. With GM-CSF effects on NK function 
still to determine and BM being logistically difficult to obtain, 
UCB derived NK  cells have been revealed as the best source 
of human material. Researchers are working on improving the 
expansion yield and purity as well as to enhance the activity of 
UCB derived NK cells before infusion in the patients. NSG mice 
demonstrated the capacity of these cells to migrate to BM, spleen, 
and liver and the inhibition of leukemia growth and prolongation 
of mice survival when combined with low-dose IL-15 (96). This 
preclinical result prompted a phase I clinical study in elderly 
AML patients that confirmed the safety and capacity of these cells 
to migrate and repopulate BM even in the absence of cytokine 
administration (97). This NK cell product aims at overcoming the 
major limitation of NK cell therapies in solid tumors, the delivery 
of high enough numbers of activated NK cells to the tumor site, 
and it is now under preclinical evaluation in the context of cervi-
cal and colorectal carcinomas (37, 98).
Alternative sources for NK  cell therapy include embryonic 
stem cell (hESC)- or induced pluripotent stem cell (iPS)-derived 
NK  cells, which are still under experimental development. 
Efficient generation of NK cells from hESC and iPS cells has been 
achieved, showing in  vitro functional cytolytic activity against 
tumor cells, IFN-γ production, and expression of functional 
receptors (99). Very few reports are available regarding the in vivo 
activity of these products, with the most encouraging being in 
a NOD/SCID mouse model in which hESC-derived NK  cells 
efficiently cleared a leukemia cell line tumor (100). Nevertheless, 
feeder-free conditions of NK cell generation need to be improved 
and the stability and safety of these NK cells products should be 
further proved in preclinical humanized models.
Finally, there is great prospect in NK cell lines as a potentially 
unlimited “pure” NK cell source. A clonal NK cell line NK-92 has 
shown the highest and most consistent cytotoxicity due to the 
combination of activating receptors it expresses and the absence 
of inhibitory KIRs (101). AML, myeloma, and melanoma are 
some of the numerous malignancies that have been partially 
eliminated from SCID mice after infusion of NK-92 (102–104). 
Clinical trials have further confirmed the safety and efficacy of 
this cell line in both solid and hematologic malignancies (105, 
106). One further advantage of NK-92 is the ease of transfection 
with non-viral vectors allowing them to express IL-2 (required for 
their proliferation), thus representing a powerful “off-the-shelf ” 
cell therapeutic (107). Additionally and inspired by the remark-
able responses obtained by CAR-T cells and the early results in 
primary NK  cells, NK-92 can be very easily transfected with 
a gene that expresses a tumor-CAR (108). The first preclinical 
tests in NSG mice have shed very optimistic results in leukemia 
models after CD19- or CD20-specific NK-92 infusions as well as 
in patient-derived glioblastoma with EGFR-specific NK-92 (109, 
110). Still, these cellular therapies retain safety concerns including 
on-target/off-tumor effects and unregulated cytotoxicity. As such, 
suicide genes (including herpes-simplex-thymidine-kinase and 
inducible caspase-9) have been integrated into these cell products 
thus allowing their subsequent selective destruction (111, 112).
The latest of the NK cell therapeutic strategies was developed 
by Vallera and colleagues with the bi- or tri-specific killer cell 
engagers, BiKEs and TriKEs that are small molecules containing 
two or three single chain variable fragments from antibodies of 
different specificities (113). These are generated to bind CD16 
on NK cells and one or two tumor antigens such as CD19 and 
CD20 (B-cell non-Hodgkin’s lymphoma) (114), CD33 or CD33 
and CD123 (AML) (115), CD30 (Hodgkin’s lymphoma) (116), 
EGFR or EpCAM (EGFR/EpCAM overexpressing carcinomas) 
(117, 118), and many others. The initial preclinical evaluation in 
humanized mice proved very promising translational potential 
with results exceeding those of monoclonal antibodies, like in 
the case of CD16-CD19-CD20 TriKE versus rituximab, and also 
proved efficient for overpassing HLA-mediated inhibition in 
refractory AML blasts.
IL-15 is the master cytokine necessary for NK cell differentia-
tion and survival and it is currently used in clinical trials alone 
or as an adjuvant for certain types of metastatic solid tumors to 
promote in vivo cell expansion and NK cell function (63, 119). 
Taking advantage of this, novel TriKE structures have been 
developed that use a human IL-15 as a modified cross-linker 
between the anti-CD16 and the antitumor antigen in order to 
promote in vivo NK cell proliferation. Assessment of the activity 
of a CD33 specific TriKE in an AML NSG model of NK cell adop-
tive transfer has shown in vivo persistence, high cytotoxic activity, 
and no toxicity to the construct (120). Clinical development is 
currently under progress and will probably obtain FDA approval 
in the upcoming months to be tested in patients.
MODeLiNG viRALLY iNDUCeD HUMAN 
TUMORS USiNG HiS MiCe
While NK  cell first identification was based on its antitumor 
activities, it is also a critical innate effector against pathogen 
invasions particularly viral infections. Human NK  cells have 
been proven essential for the immune response against members 
of the herpesvirus, poxvirus, and papillomavirus families, as 
demonstrated by the predisposition of NK deficient individuals 
to suffer from these virus infections (121, 122). Remarkably, in 
one fifth of human cancers viral infection and oncogenesis are 
intimately linked. Viruses act on carcinogenesis either by directly 
promoting the initiation of the disease or by interacting in the 
immune response and/or immune evasion (123). Particularly, 
Epstein–Barr virus (EBV), hepatitis B virus (HBV), hepatitis C 
virus (HCV), human papillomavirus, human T-cell lymphotropic 
virus, Kaposi’s sarcoma herpesvirus, and Merkel cell polyomavi-
rus account for the majority of tumor cases linked to viral infec-
tion. Humanized mice offer a platform to access the molecular 
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mechanisms behind that causal role and the receptor–ligand 
interactions occurring at the interface “NK cell-infected cell” that 
could eventually have therapeutic value. The engrafted human 
cells occupy relevant physiological sites, where they proliferate 
and function, and eventually interact with oncogenic viruses that 
spread and replicate to other cells or organs thus recapitulating 
the physiological human infection. Additionally, their unique 
susceptibility to infection by virus with exclusive human tropism 
and the possibility to manipulate the timing and dose of the 
infection render them indispensable for better understanding 
the virus–tumor interplay and disease progression as well as for 
developing therapeutic approaches.
Epstein–Barr virus is the most common human tumor virus 
worldwide (more than 200,000 associated malignancies every 
year) and is also the cause of infectious mononucleosis. It has 
been extensively studied in humanized mice modeling the dif-
ferent protein expression patterns of the virus that lead to latent 
infection 0, I, II, and III as well as low level lytic replication, 
although only latency III has been unequivocally demonstrated 
(124–129). Several studies have reported specific adaptive cellular 
and humoral immune response to EBV in humanized mice (128, 
130, 131). Furthermore, transformation of B-cell in vivo has been 
also reported and this model has disclosed one of the viral genes 
(EBNA3B) responsible for tumor formation (125). Preclinical 
studies in HIS mice have been pivotal for the development of 
the therapeutic vaccines that are now undergoing clinical trials, 
including the EBV gp350 neutralizing antibody and infusion of 
EBV-specific T cells (132). The involvement of NK cells in EBV 
infection and disease progression was demonstrated by depletion 
of NK cells from EBV-infected NSG mice resulting in higher EBV 
DNA load in the spleen, exaggerated CD8+ T-cell responses to the 
virus and an increased risk of EBV-induced lymphoproliferation 
(65). Current investigations try to deepen our understanding 
of the NK  cell-mediated control of primary EBV infection in 
HIS mice and will likely provide insight on the NK cell subset 
responsible for that viral control (133).
About 80% of hepatocellular carcinomas (HCC) are due 
to HBV or HCV infections. There are more than 250,000 new 
cases of HCC and an estimated half a million deaths due to 
this disease annually (123, 134). We and others have developed 
mouse models harboring both the immune system and human 
hepatocytes, allowing the natural course of acute infection and 
also chronic hepatitis, characterized by advanced liver disease 
and hepatocellular carcinoma genesis (17, 135, 136). In addition 
to the immunodeficiency, these mice have liver defects that allow 
engraftment and expansion of transplanted human hepatocytes. 
Several immune system–liver humanized models have been 
developed, including BRGS-uPA (BALB/c Rag2−/−Il2rg−/−SirpaNOD 
uPAtg/tg) (17), uPA-NOG (uPA-NOD PrkdcSCIDIl2rg−/−) (135), 
and FRGN (Fah−/−Rag2−/−Il2rg−/− NOD) (136). These doubly 
humanized mice show high level of human liver chimerism 
and immune engraftment in primary and secondary lymphoid 
organs with reconstitution of myeloid and lymphoid populations 
at levels similar to the single HIS models. In BRGS-uPA mice, 
NK cells are present in spleen and liver in numbers even higher 
than BRGS mice and display the same NK receptor expression 
profile (unpublished data). Infection with HBV and HCV has 
been achieved in these mice and human immune responses have 
been detected as well as associated liver diseases that resemble the 
human pathology. Furthermore, both mimic the clinical response 
upon treatment with anti-HBs neutralizing antibodies and 
IFNα-2an, respectively, and prevented the leukocyte infiltration 
and liver fibrosis (137, 138). Any in depth analysis of the NK cell 
response against the virus or the role in tumorigenesis has been 
so far performed in these mice, other than the detection of CD56+ 
cells, to our knowledge.
iMPROviNG THe NK CeLL 
COMPARTMeNT iN HiS MiCe
Given the central role of NK cells in immune responses in infec-
tion, malignancy and inflammation and the great therapeutic 
potential they hold, it is necessary to optimize the available 
models for understanding their biology and preclinically evaluate 
new therapies.
In previous sections, we discussed about two types of HIS 
mice for the study of NK cell biology, those in which the human 
immune cells develop in  vivo from injected hematopoietic 
precursors and a second category that adoptively receive mature 
NK cells freshly isolated or derived from an ex vivo expansion or 
activation process, a cell line or an ES or iPS cell. The later have 
fewer requirements in terms of niche, cell–cell interactions, and 
soluble growth factors that are needed for NK cell development, 
and instead require cytokines for their survival and homeostatic 
proliferation. Common cytokine receptor γc cytokines (IL-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21) play critical roles. In particular, 
IL-15 is responsible for NK  cell maintenance and homeostatic 
proliferation through IL-15Rα presentation (139, 140), while 
IL-2 effect in vivo is oriented to the activation and induction of 
cytotoxicity through the regulation of the peripheral NK subsets. 
These humanized mice serve as platforms to understand the 
mechanisms underlying NK survival and function and provide 
preclinical information for the design of new therapeutics. 
Furthermore, they give valuable information about the cell 
migration capacity and synergistic effects with other cell types or 
immunomodulators.
As mentioned earlier, several immunodeficient hosts (NSG, 
NOG, BRG, BRGS) support multilineage development of human 
immune cells, including low levels of NK  cells. In the BRGS 
model (16, 141), NK cells expressed CD56 and NKp46 as well as 
some level of CD16 and were able to degranulate moderately after 
stimulation with a cancer cell line. However, in both BRGS and 
NSG mice, NK cell displayed defects in maturation, functionality, 
and heterogeneity in comparison with the human counterparts 
due to a deficient cytokine signaling (142). The absence of human 
appropriate MHC class I expression on hematopoietic or stromal 
cells may result in the failure to “educate” or “license” develop-
ing NK cells in HIS mice. This could explain the abundance of 
immature NK cells (CD56brightCD16−KIR−) and their functional 
defects. In line with this idea, recent publications showed 
improved NK cell licensing in a HIS models expressing diverse 
educating HLA alleles (143, 144). This approach may allow better 
definition of the mechanisms underlying human NK cell educa-
tion in vivo.
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Based on their cytokine requirements, IL-15 has been exog-
enously administered either alone or as a complex with IL-15Rα 
resulting in an extensive NK cell proliferation and accumulation of 
CD16+KIR+ NK cells. Also, NK cell differentiation progressed from 
CD56+ to CD56lowCD16+, and finally to CD56lowCD16+KIR+ mim-
icking the human model (63). On the other hand, the constitutive 
high expression of the high-affinity heterotrimeric IL-2 receptor 
complex in CD56brightCD16± NK-cell subset and the effect of IL-2 
in NK expansion and activation prompted the development of and 
IL-2 transgenic NOG mouse strain (145). When IL-2TgNOG mice 
were engrafted with human HSC, CD56+ massively developed with 
a highly active phenotype including IFN-γ production and cyto-
toxicity against tumor cells. Interestingly, treatment of these mice 
with a therapeutic humanized anti-CCR4 Ab (mogamulizumab) 
suppressed the growth of a CCR4+ lymphoma, suggesting that the 
human NK cells in the mice exerted active Ab-dependent cellular 
cytotoxicity in vivo. These cells expressed various NK receptors, 
including NKp30, NKp44, NKp46, NKG2D, and CD94, as well 
as a diverse set of killer cell Ig-like receptor molecules at levels 
comparable to normal human NK cells from the peripheral blood 
(62). Nevertheless, there are several limitations in this model due 
to the supra-physiological levels of IL-2 and, therefore, the high 
activation status of the NK cells.
It is well known that NK homeostasis and function are 
regulated by the interaction with other immune cells, particu-
larly macrophages, DCs, and T cells. In addition, soluble factors 
released by those cells, like NKG2D ligands, IL-2, IL-12, or IL-15, 
signal on NK cells leading to proliferation and activation. Based 
on these crosstalk events, others and we have developed human-
ized mice that through the enhancement of the myeloid compart-
ment, NK cell development results improved. As it happens for 
other lineages, human myelopoiesis is driven by soluble factors 
normally present in the BM niche and periphery, which are from 
murine origin in HIS mice. Some of these mouse cytokines cross-
react to some extent with the human cells but others, the species-
specific cytokines, do not. In order to circumvent this deficiency, 
human cytokines have been administered to HIS mice either as 
recombinant proteins (63) by cytokine-encoding plasmids (146) 
or by insertion of the cytokines either as transgenes in the mouse 
genome or by knocking in the human gene to replace the mouse 
counterpart (147, 148). As mentioned before, transgenic models 
provoke supra-physiological levels of the cytokine in the periph-
ery and in the case of pro-myeloid factors, such as TPO, IL-3, 
GM-CSF, or M-CSF, also lead to the exacerbated mobilization 
and HSC exhaustion limiting the utility of the system. Swapping 
mouse coding exons for M-CSF, IL-3/GM-CSF, TPO, and SIRPα 
with their human counterparts allowed for the creation of the 
MISTRG strain (149). This host expresses these human cytokines 
under control of mouse regulatory elements and show superior 
human myeloid cell engraftment. Subsequently, MISTRG HIS 
mice showed an increased number of functional NK  cells, 
including higher expression of KIR, CD94, and CD161 receptors 
(149). Nevertheless, cellular and humoral immune responses 
in MISTRG HIS mice are poor and these mice develop severe 
anemia.
The transpresentation of IL-15 occurs mainly through the 
IL-15Rα expressed by DCs, so efforts have been made to increase 
specifically this cell population in order to increase the NK 
pool avoiding the overdevelopment of other myeloid subsets. In 
our laboratory, Flt3-deficient BRG mice (BRGF) were created 
and after reconstitution with human HSC, human Flt3L was 
administered to the mice. The result was a specific increase of 
all the DC subsets and the promotion of NK cell hematopoiesis, 
with enhanced CD94, CD16, and KIR receptor expression. The 
combination of this system with the expression of the SirpaNOD 
protein in the BRGSF model has led to further augmentation of 
NK cell numbers and also an enhanced functional competency 
as demonstrated by their degranulation capacity and cytokine 
production activity (unpublished data). This HIS model provides 
a unique platform to study NK  cell development, crosstalk 
mechanisms with other immune cells, and the preclinical assess-
ment of new immunotherapies targeting innate cells.
The combination of the protocols detailed in the previous 
sections for modeling human cancer or infection with the 
abovementioned strategies to boost the NK  cells in HIS mice 
will raise the potential to understand how NK cell interact with 
malignant or infected cells. Moreover, HSC-HIS mice offer the 
possibility to study the tissue specific interactions, the reservoirs, 
the migration patterns, and the crosstalks within the immune 
compartment that may be important to develop combinatorial 
therapies that avoid metastasis, tumor relapse, and “relocation” 
of the viruses.
CONCLUDiNG ReMARKS AND FUTURe 
PeRSPeCTiveS
Therapies designed to induce or potentiate the immune response 
against tumors are an appealing strategy to control tumor growth 
and have been the object of intense research since their discovery 
in the 1970s. Despite representing the most promising cancer 
treatment since the emergence of chemotherapy, several cases of 
side effects or disappointing clinical results have downshifted the 
development of new immunotherapies. The better understand-
ing of the tumor heterogeneity, the mechanisms of the immune 
response, and the interaction with the tumor microenvironment 
is a required step for the development of safe and effective 
therapies. Humanized mice have the potential to reproduce the 
HIS, the tumor growth and immune evasion, and the response to 
treatments targeting immune effector cells or immunomodula-
tors. One of the most challenging aspects of tumor research has 
been to understand the variability within he same type of cancer 
among individuals and, therefore, the disparate responses and 
outcomes after therapy. Current efforts are being made to over-
come these limitations by creating truly personalized HIS-PDX 
mouse models in which both the immune system and the tumor 
are derived form the same individual. These models will provide 
an invaluable bridge between immunotherapy discovery and the 
clinic, increasing the success rate of new therapies in human trials 
and improving the chances to beat cancer.
Natural killer cells have been for long time considered the only 
innate effectors of the lymphoid system but nowadays we appreci-
ate that they belong to a larger family, the “innate lymphoid cells” 
(ILCs) (150). These recently described populations lack cytotoxic 
capacity but instead, they exert very potent cytokine production. 
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In recent years, there has been a rapid advance in our understand-
ing of their development, phenotypic, and functional diversity, 
which has been nicely reviewed elsewhere (151–155). ILCs 
come in three groups mirroring the cytokine and transcriptional 
profile of CD4+ helper T cells (Th1, Th2, and Th17/22). Given the 
myriad of cytokines they produce, ILCs have been involved in 
the early orchestration of immune responses against a number of 
pathogens, in tumor immunosurveillance and in inflammatory 
diseases. Recent works in mice have proven the antitumor effects 
of ILC1s whereas ILC3s have been found to exert both beneficial 
and tumor-promoting effects depending on the circumstances 
(156–158). The multifaceted functions of ILCs suggest new alter-
natives for immunotherapeutic approaches against tumors that 
need to be explored in in vivo humanized models. The improve-
ment of human helper ILCs in HIS mice could open new avenues 
for harnessing innate immunity to treat cancer and inflammatory 
diseases.
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